BioCentury | Jul 29, 2020
Politics, Policy & Law

Alliance for Regenerative Medicine sees advanced therapies as pilot for EU's regular use of real-world evidence

...initiative; and the Heads of Medicines Agencies (HMA) and EMA Joint Big Data Taskforce and DARWIN...
BioCentury | Feb 5, 2020
Regulation

EMA’s plan to integrate real-world data across Europe

...of EMA’s top priorities for incorporating real-world data earlier in the regulatory process is establishing DARWIN...
...Big Data Taskforce. Together with the Heads of Medicines Agencies (HMA), EMA plans to launch DARWIN...
...World Interrogation Network) by 2023. "The regulator network needs to be data-driven." Peter Arlett, EMA DARWIN...
BioCentury | Jun 18, 2019
Company News

Google partnership latest in Sanofi's quest to integrate digital throughout its business

...behavioral health tracking platform to better manage population health. That same year, Sanofi launched its DARWIN...
BioCentury | Jan 11, 2016
Strategy

Growing up Galapagos

...of an improvement in ACR20 at 12 weeks in the Phase IIb DARWIN 1 and DARWIN...
...Comparing JAK-1s Trial Population Dosage No. patients ACR20 at 12 weeks P-value Filgotinib Ph IIb DARWIN...
...twice daily 85 59% Not reported 100 mg twice daily 84 80% <0.001 Ph IIb DARWIN...
BioCentury | Sep 25, 2015
Company News

AbbVie snubs Galapagos, takes own JAK-1 into Phase III

...statistically significant vs. placebo. In April, Galapagos announced 12-week efficacy data for the Phase IIb DARWIN...
BioCentury | Aug 17, 2015
Clinical News

Filgotinib: Phase IIb final data

...Final data from the double-blind, placebo-controlled, international Phase IIb DARWIN 2 trial in 283 patients with...
BioCentury | Aug 17, 2015
Clinical News

Filgotinib: Completed Phase II enrollment

...and commercialize GLPG0634 for rheumatoid arthritis (RA) and CD. Upon completion of the Phase II DARWIN...
BioCentury | Aug 3, 2015
Clinical News

Filgotinib: Phase IIb final data

...Final data from the double-blind, international Phase IIb DARWIN 1 trial in 594 patients with moderate...
BioCentury | Jul 31, 2015
Top Story

Galapagos reports additional Phase IIb filgotinib data in RA

...Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported 24-week data from the Phase IIb DARWIN 1 trial of filgotinib...
...Disease Activity Score using 28 joint counts (DAS28). Galapagos expects data from the Phase IIb DARWIN...
BioCentury | Jul 13, 2015
Finance

Big news

...said Muijrers. In July, Galapagos is slated to report full results from the Phase IIb DARWIN...
...about safety." In August, Galapagos is slated to report additional data from the Phase IIb DARWIN...
...NYSE:ABBV) Filgotinib (GLPG0634) Rheumatoid arthritis (RA) Top-line Ph IIb DARWIN 1 data; Top-line Ph IIb DARWIN...
Items per page:
1 - 10 of 56
BioCentury | Jul 29, 2020
Politics, Policy & Law

Alliance for Regenerative Medicine sees advanced therapies as pilot for EU's regular use of real-world evidence

...initiative; and the Heads of Medicines Agencies (HMA) and EMA Joint Big Data Taskforce and DARWIN...
BioCentury | Feb 5, 2020
Regulation

EMA’s plan to integrate real-world data across Europe

...of EMA’s top priorities for incorporating real-world data earlier in the regulatory process is establishing DARWIN...
...Big Data Taskforce. Together with the Heads of Medicines Agencies (HMA), EMA plans to launch DARWIN...
...World Interrogation Network) by 2023. "The regulator network needs to be data-driven." Peter Arlett, EMA DARWIN...
BioCentury | Jun 18, 2019
Company News

Google partnership latest in Sanofi's quest to integrate digital throughout its business

...behavioral health tracking platform to better manage population health. That same year, Sanofi launched its DARWIN...
BioCentury | Jan 11, 2016
Strategy

Growing up Galapagos

...of an improvement in ACR20 at 12 weeks in the Phase IIb DARWIN 1 and DARWIN...
...Comparing JAK-1s Trial Population Dosage No. patients ACR20 at 12 weeks P-value Filgotinib Ph IIb DARWIN...
...twice daily 85 59% Not reported 100 mg twice daily 84 80% <0.001 Ph IIb DARWIN...
BioCentury | Sep 25, 2015
Company News

AbbVie snubs Galapagos, takes own JAK-1 into Phase III

...statistically significant vs. placebo. In April, Galapagos announced 12-week efficacy data for the Phase IIb DARWIN...
BioCentury | Aug 17, 2015
Clinical News

Filgotinib: Phase IIb final data

...Final data from the double-blind, placebo-controlled, international Phase IIb DARWIN 2 trial in 283 patients with...
BioCentury | Aug 17, 2015
Clinical News

Filgotinib: Completed Phase II enrollment

...and commercialize GLPG0634 for rheumatoid arthritis (RA) and CD. Upon completion of the Phase II DARWIN...
BioCentury | Aug 3, 2015
Clinical News

Filgotinib: Phase IIb final data

...Final data from the double-blind, international Phase IIb DARWIN 1 trial in 594 patients with moderate...
BioCentury | Jul 31, 2015
Top Story

Galapagos reports additional Phase IIb filgotinib data in RA

...Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported 24-week data from the Phase IIb DARWIN 1 trial of filgotinib...
...Disease Activity Score using 28 joint counts (DAS28). Galapagos expects data from the Phase IIb DARWIN...
BioCentury | Jul 13, 2015
Finance

Big news

...said Muijrers. In July, Galapagos is slated to report full results from the Phase IIb DARWIN...
...about safety." In August, Galapagos is slated to report additional data from the Phase IIb DARWIN...
...NYSE:ABBV) Filgotinib (GLPG0634) Rheumatoid arthritis (RA) Top-line Ph IIb DARWIN 1 data; Top-line Ph IIb DARWIN...
Items per page:
1 - 10 of 56